A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Global Artificial Insemination Market Report 2022 to 2027: Increasing Awareness Among Individuals About Alternative Reproductive Treatments Drives Growth

The global artificial insemination market reached a value of US$ 1.9 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 3.0 Billion by 2027, exhibiting a CAGR of 7.91% during 2021-2027.

Companies Mentioned

  • Conceivex Inc.
  • FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation)
  • Genea Limited
  • Genus plc
  • Hamilton Thorne Inc.
  • Hi-Tech Solutions
  • Kitazato Corporation
  • Pride Angel
  • Rinovum Women’s Health LLC
  • Rocket Medical plc
  • TenderNeeds Fertility LLC
  • Vitrolife AB

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Artificial insemination is an assisted reproductive treatment wherein semen with living sperms is introduced into the cervix, fallopian tubes, or uterus of a female. It is performed via artificial insemination homologous (AIH) or artificial insemination donor semen (AID) procedures that are short and relatively painless.

Self-insemination kits are nowadays available in the market that can be used at the convenience of home. At present, artificial insemination is widely being used in animal breeding to facilitate the reproductive success and conservation of threatened or endangered species. It also prevents the spread of certain diseases and sterility due to genital conditions in animals.

The rising infertility rates, along with the increasing awareness among individuals about alternative reproductive treatments, represent one of the significant factors influencing the market.

Moreover, governments of numerous countries have legalized same-sex marriage and are providing insurance coverage to civil unions for artificial insemination procedures, which is also contributing to the market growth.

Apart from this, the rising global population and the escalating demand for animal-based protein are fueling the need for artificial insemination among domestic livestock animals. Improving veterinary services and rising expenditure on animal healthcare is also supporting the market growth.

Furthermore, the leading players are entering into strategic collaborations for expanding their portfolio of animal genetic and strengthening their position in different markets.

For instance, Genus plc, which is a leading animal genetics company, partnered with Beijing Capital Agribusiness Co. Ltd, a leading Chinese animal protein genetics business, to research and develop virus-resistant techniques in pigs.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global artificial insemination market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, source type and end use.

Breakup by Type:

  • Intrauterine
  • Intracervical
  • Intravaginal
  • Intratubal

Breakup by Source Type:

  • AIH-Husband
  • AID-Donor

Breakup by End Use:

  • Hospitals and Clinics
  • Fertility Centers
  • Others

Breakup by Region:

North America

  • United States
  • Canada

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others

Latin America

  • Brazil
  • Mexico
  • Others

Middle East and Africa

Key Questions Answered in This Report:

  • How has the global artificial insemination market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global artificial insemination market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the source type?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global artificial insemination market and who are the key players?
  • What is the degree of competition in the industry?

For more information about this report visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy